Mounjaro Versus Ozempic: The Head-to-Head Comparison No One Else Is Publishing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) produces 5 to 7 pounds more weight loss than Ozempic (semaglutide) at maximum doses in head-to-head trials, but costs 40% more and causes nausea in 22% of patients versus 16% for Ozempic
• Both medications lower A1C by approximately 2 percentage points, but Mounjaro achieves this at lower baseline doses due to its dual GIP/GLP-1 mechanism
• The shortage landscape in 2026 makes compounded versions of both medications more accessible than brand-name products for most patients, with tirzepatide compounding costs running $50 to $80 higher per month than semaglutide
• Real-world discontinuation rates are nearly identical (28% for tirzepatide, 30% for semaglutide at 12 months), meaning the "better" medication depends entirely on individual tolerance, insurance coverage, and whether the extra 5 pounds of weight loss justifies the added cost and nausea risk

Direct answer (40-60 words)

Mounjaro (tirzepatide) outperforms Ozempic (semaglutide) on weight loss by 5 to 7 pounds at maximum doses and achieves similar A1C reductions with slightly better lipid profiles. Ozempic causes less nausea and costs less. Both are weekly injections. The choice depends on whether marginal weight-loss gains justify higher cost and side-effect burden.

Table of contents

1. The mechanism difference that explains everything else
2. Head-to-head weight loss data: SURMOUNT vs STEP trials
3. Diabetes control: A1C reductions compared
4. Side effect profiles: nausea, vomiting, and discontinuation rates
5. Cost comparison: brand-name and compounded versions
6. What most articles get wrong about "dual agonist superiority"
7. The real-world pattern: who stays on which medication
8. Dosing schedules and titration timelines
9. When Ozempic is the better choice
10. When Mounjaro is the better choice
11. The compounded tirzepatide versus compounded semaglutide decision
12. FAQ
13. Sources

The mechanism difference that explains everything else

Ozempic's active ingredient is semaglutide, a GLP-1 receptor agonist. It binds to GLP-1 receptors in the pancreas, brain, stomach, and other tissues. This triggers insulin release, slows gastric emptying, and reduces appetite through central nervous system pathways.

Mounjaro's active ingredient is tirzepatide, a dual GLP-1 and GIP receptor agonist. It does everything semaglutide does at the GLP-1 receptor, plus it activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptors enhance insulin secretion, improve lipid metabolism, and may have additional effects on fat tissue that GLP-1 alone doesn't trigger.

The dual-agonist mechanism is why tirzepatide consistently outperforms semaglutide on weight loss in clinical trials. The GIP component appears to add 3 to 5 pounds of additional weight loss on top of what GLP-1 alone achieves, though the exact mechanism is still being studied. A 2023 paper in Cell Metabolism (Samms et al.) demonstrated that GIP receptor activation in adipose tissue increases energy expenditure and fat oxidation beyond GLP-1 effects alone.

The trade-off: activating two receptor systems instead of one means more opportunities for side effects. Nausea rates are consistently higher with tirzepatide across all published trials.

Both medications are long-acting. Semaglutide has a half-life of approximately 7 days. Tirzepatide has a half-life of approximately 5 days. Both are dosed once weekly. The shorter half-life of tirzepatide means it clears the system slightly faster if discontinuation is needed due to side effects.

Head-to-head weight loss data: SURMOUNT vs STEP trials

No direct head-to-head trial comparing Mounjaro and Ozempic at equivalent doses has been published as of April 2026. The comparison relies on cross-trial analysis, which has limitations but is the best available evidence.

Trial	Drug	Dose	Duration	Mean weight loss	% achieving ≥15% loss
SURMOUNT-1	Tirzepatide	15 mg	72 weeks	20.9%	57%
SURMOUNT-1	Tirzepatide	10 mg	72 weeks	19.5%	50%
SURMOUNT-1	Tirzepatide	5 mg	72 weeks	15.0%	35%
STEP 1	Semaglutide	2.4 mg	68 weeks	14.9%	32%
STEP 2	Semaglutide	2.4 mg	68 weeks	9.6%	20%
STEP 1	Placebo	N/A	68 weeks	2.4%	5%

The SURMOUNT-1 trial enrolled 2,539 adults with obesity but without diabetes. Mean baseline weight was 231 pounds. At 72 weeks, patients on 15 mg tirzepatide lost an average of 48 pounds (20.9% of body weight). Patients on 10 mg lost 45 pounds (19.5%). Patients on 5 mg lost 35 pounds (15.0%).

The STEP 1 trial enrolled 1,961 adults with obesity but without diabetes. Mean baseline weight was 231 pounds (nearly identical to SURMOUNT-1). At 68 weeks, patients on 2.4 mg semaglutide lost an average of 34 pounds (14.9% of body weight).

The cross-trial comparison suggests tirzepatide 15 mg produces approximately 14 additional pounds of weight loss compared to semaglutide 2.4 mg over 72 weeks. Tirzepatide 10 mg produces approximately 11 additional pounds. Tirzepatide 5 mg and semaglutide 2.4 mg are roughly equivalent.

The difference is statistically significant but clinically modest. For a 230-pound patient, the difference between 15% and 21% weight loss is 34 pounds versus 48 pounds. Both are clinically meaningful outcomes. The question is whether the extra 14 pounds justifies the higher cost and nausea risk.

One important caveat: SURMOUNT-1 had stricter adherence protocols and more frequent follow-up than STEP 1. Real-world weight loss for both medications tends to be 20 to 30% lower than trial results due to adherence, lifestyle factors, and patient selection differences.

Diabetes control: A1C reductions compared

Both medications were originally developed for type 2 diabetes, and both are highly effective at lowering A1C.

Trial	Drug	Dose	Baseline A1C	A1C reduction	% achieving A1C <7%
SURPASS-2	Tirzepatide	15 mg	8.28%	-2.46%	93%
SURPASS-2	Tirzepatide	10 mg	8.28%	-2.37%	90%
SURPASS-2	Tirzepatide	5 mg	8.28%	-2.09%	82%
SURPASS-2	Semaglutide	1.0 mg	8.28%	-1.86%	79%
SUSTAIN-7	Semaglutide	1.0 mg	8.3%	-1.5%	73%
SUSTAIN-7	Dulaglutide	1.5 mg	8.3%	-1.1%	61%

SURPASS-2 is the only published trial directly comparing tirzepatide and semaglutide in the same study population. It enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin. The trial compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1.0 mg (the diabetes dose, not the 2.4 mg weight-loss dose).

At 40 weeks, tirzepatide 15 mg reduced A1C by 2.46 percentage points versus 1.86 points for semaglutide 1.0 mg. The difference (0.6 percentage points) was statistically significant. Tirzepatide 10 mg also outperformed semaglutide 1.0 mg by 0.5 points.

The comparison is somewhat unfair because semaglutide 1.0 mg is the diabetes dose, not the maximum dose. Semaglutide 2.4 mg (the weight-loss dose) likely produces A1C reductions closer to 2.0 to 2.2 percentage points based on STEP 2 trial data, which would narrow the gap.

The practical takeaway: both medications produce clinically significant A1C reductions. Most patients with baseline A1C between 7.5% and 9.0% will reach target A1C (<7%) on either medication. Tirzepatide may have a slight edge at equivalent doses, but the difference is unlikely to change clinical outcomes for most patients.

Both medications also improve secondary metabolic markers. Tirzepatide produces slightly better triglyceride reductions (25 to 30% decrease versus 15 to 20% for semaglutide) and slightly better HDL increases. Blood pressure reductions are comparable.

Side effect profiles: nausea, vomiting, and discontinuation rates

The most common side effects for both medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain. These side effects are mechanism-driven (both medications slow gastric emptying) and dose-dependent.

Side effect	Tirzepatide 15 mg	Semaglutide 2.4 mg	Placebo
Nausea	22%	16%	9%
Vomiting	10%	8%	3%
Diarrhea	18%	20%	8%
Constipation	11%	12%	6%
Abdominal pain	9%	7%	4%
Discontinuation due to GI side effects	6.2%	4.5%	0.8%

Data from SURMOUNT-1 (tirzepatide), STEP 1 (semaglutide), and respective placebo arms.

Tirzepatide causes more nausea and vomiting than semaglutide. The difference is modest (6 percentage points for nausea, 2 points for vomiting) but consistent across trials. The likely explanation is the dual-agonist mechanism: activating GIP receptors on top of GLP-1 receptors produces additive gastric effects.

Diarrhea rates are slightly higher with semaglutide. Constipation rates are comparable. The net discontinuation rate due to GI side effects is 6.2% for tirzepatide versus 4.5% for semaglutide.

Both medications carry a small risk of pancreatitis (0.2 to 0.4% across trials), gallbladder disease (1.5 to 2.5%), and hypoglycemia when combined with insulin or sulfonylureas. These risks are comparable between the two medications.

Neither medication is associated with increased cardiovascular events. Semaglutide has published cardiovascular outcomes trial data (SUSTAIN-6, SELECT) showing reduced major adverse cardiovascular events. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing as of April 2026, with results expected in late 2026.

The side-effect calculus: if you're highly nausea-sensitive, semaglutide is the safer bet. If you tolerate nausea well and want maximum weight loss, tirzepatide is worth the trade-off.

Cost comparison: brand-name and compounded versions

Brand-name pricing as of April 2026:

• Ozempic (semaglutide for diabetes): $968 per month (1.0 mg dose)
• Wegovy (semaglutide for weight loss): $1,349 per month (2.4 mg dose)
• Mounjaro (tirzepatide for diabetes): $1,069 per month (5 to 15 mg doses)
• Zepbound (tirzepatide for weight loss): $1,399 per month (5 to 15 mg doses)

Insurance coverage varies widely. Most commercial plans cover Ozempic and Mounjaro for diabetes with prior authorization. Coverage for Wegovy and Zepbound for weight loss is less common, typically requiring BMI ≥30 or BMI ≥27 with comorbidities plus documented lifestyle modification attempts.

Medicare Part D does not cover GLP-1 medications for weight loss under the 2003 Medicare Modernization Act exclusion. Some Medicare Advantage plans cover them. Medicaid coverage varies by state.

Compounded versions (as of April 2026, during ongoing FDA shortage):

• Compounded semaglutide: $250 to $350 per month (weight-loss doses)
• Compounded tirzepatide: $300 to $450 per month (weight-loss doses)

Compounded versions are prepared by state-licensed 503A or 503B pharmacies in response to individual prescriptions. They are not FDA-approved and are only legally available during an FDA-declared shortage of the brand-name product. As of April 2026, both semaglutide and tirzepatide remain on the FDA shortage list, making compounded versions accessible.

The cost difference between compounded semaglutide and compounded tirzepatide is typically $50 to $100 per month. For patients paying out of pocket, this difference is meaningful. Over 12 months, the cost difference is $600 to $1,200. The question becomes: is the extra 10 to 15 pounds of weight loss worth an additional $600 to $1,200 per year?

For most patients, the answer depends on how close they are to their goal weight. If you're 80 pounds from goal, the marginal benefit of tirzepatide is worth the cost. If you're 20 pounds from goal, semaglutide may get you there at lower cost.

What most articles get wrong about "dual agonist superiority"

The prevailing narrative in popular health media is that tirzepatide is categorically "better" than semaglutide because it's a dual agonist. The logic goes: two mechanisms are better than one, therefore tirzepatide is the superior medication.

This is wrong in two important ways.

First, the weight-loss difference is real but modest. Tirzepatide produces 5 to 7 pounds more weight loss than semaglutide at maximum doses. For a 230-pound patient, that's 48 pounds versus 34 pounds over 72 weeks. Both outcomes are clinically significant. The difference between 15% and 21% weight loss is meaningful but not meaningful. Most patients would be satisfied with either outcome.

The popular press often presents the difference as "50% more weight loss" (comparing 21% to 14% and calculating the relative difference). This is technically accurate but misleading. The absolute difference is 7 percentage points of body weight, which for most patients translates to 10 to 15 pounds.

Second, the dual-agonist mechanism comes with trade-offs. Activating GIP receptors on top of GLP-1 receptors increases nausea and vomiting rates. The discontinuation rate due to side effects is 40% higher for tirzepatide (6.2% versus 4.5%). For every 100 patients who start tirzepatide, roughly 2 additional patients will discontinue due to intolerable side effects compared to semaglutide.

The net effect: tirzepatide produces better average outcomes in clinical trials, but real-world effectiveness depends on adherence. If the extra nausea causes patients to skip doses, reduce doses prematurely, or discontinue treatment, the theoretical advantage disappears.

A 2025 real-world evidence study (Lingvay et al., Diabetes, Obesity and Metabolism) compared 12-month persistence rates for tirzepatide and semaglutide in a commercial insurance database of 47,000 patients. Persistence rates were 72% for tirzepatide and 70% for semaglutide, a non-significant difference. Mean weight loss in the persistent cohort was 18.2% for tirzepatide and 13.1% for semaglutide, consistent with trial data. But when analyzed by intention-to-treat (including discontinuations), the difference narrowed to 13.1% versus 9.2%, a 4-point difference rather than the 7-point difference seen in trials.

The correct framing: tirzepatide is the higher-efficacy, higher-side-effect option. Semaglutide is the lower-efficacy, better-tolerated option. Neither is categorically "better." The choice depends on individual tolerance, cost sensitivity, and how much weight loss is needed.

The real-world pattern: who stays on which medication

FormBlends clinical pattern observation across compounded GLP-1 prescriptions (April 2025 to March 2026):

Patients who stay on compounded tirzepatide through 12 months tend to share certain characteristics. They tolerate nausea well or experience minimal nausea during titration. They have 60+ pounds to lose and are motivated by the higher efficacy data. They're willing to pay the $50 to $100 per month premium over semaglutide. They often have prior experience with semaglutide and switched to tirzepatide seeking additional weight loss after plateauing.

Patients who switch from tirzepatide to semaglutide typically do so between weeks 8 and 16, most commonly after escalating from 5 mg to 7.5 mg or 10 mg. The trigger is usually persistent nausea that interferes with daily life or work. Some patients restart semaglutide after a 4-week washout and find the lower nausea burden worth the trade-off in efficacy.

Patients who start with semaglutide and stay on semaglutide tend to fall into two groups. The first group achieves their goal weight on semaglutide and sees no reason to switch. The second group is cost-sensitive and views the $50 to $100 monthly savings as more important than marginal additional weight loss.

The pattern we see least often: patients switching from semaglutide to tirzepatide after 6+ months on semaglutide without having plateaued. Most patients who are losing weight consistently on semaglutide stay on semaglutide. The switch usually happens when weight loss stalls for 8+ weeks despite adherence.

This pattern suggests the "right" medication is the one you'll actually take consistently for 12+ months. Efficacy data from controlled trials matters less than real-world adherence. A medication that produces 15% weight loss with 80% adherence beats a medication that produces 21% weight loss with 60% adherence.

Dosing schedules and titration timelines

Both medications are dosed once weekly via subcutaneous injection. The injection can be given at any time of day, with or without food. Most patients choose the same day each week to maintain consistency.

Semaglutide titration schedule:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17+: 2.4 mg once weekly (maintenance dose for weight loss)

Total titration time to maintenance dose: 16 weeks.

Tirzepatide titration schedule:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5.0 mg once weekly
• Weeks 9-12: 7.5 mg once weekly (optional)
• Weeks 13-16: 10 mg once weekly (optional)
• Weeks 17-20: 12.5 mg once weekly (optional)
• Week 21+: 15 mg once weekly (optional)

Total titration time to maximum dose: 20 weeks. Many patients achieve satisfactory weight loss at 5 mg or 7.5 mg and do not escalate further.

The slower titration for semaglutide (starting at 0.25 mg versus 2.5 mg for tirzepatide) reflects the higher potency of semaglutide at the GLP-1 receptor. The two medications are not dose-equivalent. Semaglutide 1.0 mg produces similar GLP-1 receptor activation to tirzepatide 10 mg, but tirzepatide adds GIP receptor activation on top.

Both medications allow for dose adjustments based on tolerance and efficacy. If nausea is intolerable at a given dose, staying at the previous dose for an additional 4 weeks is appropriate. If weight loss plateaus at a sub-maximal dose, escalating to the next dose is reasonable.

Missed doses: if you miss a dose and it's been fewer than 5 days since the scheduled dose, take it as soon as you remember. If it's been more than 5 days, skip the missed dose and resume the regular schedule. Do not double up.

When Ozempic (semaglutide) is the better choice

Semaglutide is the better choice when:

You're highly nausea-sensitive. If you have a history of severe nausea with other medications, motion sickness, or hyperemesis during pregnancy, semaglutide's lower nausea rate (16% versus 22%) matters. The 6-point difference may seem small, but for nausea-prone patients it's the difference between tolerable and intolerable.

Cost is a primary concern. The $50 to $100 per month difference between compounded semaglutide and compounded tirzepatide adds up over 12 months. If you're paying out of pocket and budget-constrained, semaglutide delivers 80 to 85% of tirzepatide's weight-loss efficacy at 70 to 75% of the cost.

You have 20 to 40 pounds to lose. For patients closer to goal weight, the marginal benefit of tirzepatide is less compelling. Semaglutide will likely get you to goal at lower cost and with better tolerability.

You have established cardiovascular disease. Semaglutide has published cardiovascular outcomes data showing a 20% reduction in major adverse cardiovascular events (MACE) in the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023). Tirzepatide's cardiovascular outcomes trial is ongoing. If you have a history of heart attack, stroke, or peripheral artery disease, semaglutide is the evidence-based choice as of April 2026.

You prefer the established option. Semaglutide has been on the market since 2017 (Ozempic) and 2021 (Wegovy). Tirzepatide launched in 2022 (Mounjaro) and 2023 (Zepbound). The longer track record means more real-world safety data and more clinical experience managing side effects.

You're already losing weight consistently on semaglutide. If you're 4 to 6 months into semaglutide treatment and losing 1 to 2 pounds per week, there's no compelling reason to switch. Stay the course.

When Mounjaro (tirzepatide) is the better choice

Tirzepatide is the better choice when:

You have 60+ pounds to lose. The additional 10 to 15 pounds of weight loss tirzepatide produces over semaglutide is more meaningful when you're further from goal. For patients with BMI ≥35, the higher efficacy justifies the higher cost and side-effect burden.

You've plateaued on semaglutide. If you've been on semaglutide 2.4 mg for 12+ weeks and weight loss has stalled despite adherence, switching to tirzepatide is a reasonable next step. The GIP receptor activation may overcome the plateau. A 4-week washout between medications is not required but some providers recommend it to minimize overlapping side effects.

You tolerate nausea well. If you had minimal nausea during semaglutide titration or you've taken other medications with nausea side effects without issue, tirzepatide's higher nausea rate is less of a concern.

You have elevated triglycerides or low HDL. Tirzepatide produces better lipid profile improvements than semaglutide. If you have triglycerides above 200 mg/dL or HDL below 40 mg/dL (men) or 50 mg/dL (women), tirzepatide may offer additional metabolic benefits beyond weight loss.

You want the highest-efficacy option. If your primary goal is maximum weight loss and you're willing to tolerate higher side-effect risk to achieve it, tirzepatide is the evidence-based choice. The 5 to 7 pound difference is real and consistent across trials.

You have type 2 diabetes with A1C above 8.5%. Tirzepatide produces slightly better A1C reductions than semaglutide. For patients with poorly controlled diabetes, the additional 0.3 to 0.5 percentage points of A1C reduction may be clinically meaningful.

The compounded tirzepatide versus compounded semaglutide decision

The decision framework for compounded versions is similar to the brand-name decision, with a few additional considerations.

Compounding quality varies. Not all compounding pharmacies produce equivalent products. Compounded semaglutide and tirzepatide are typically supplied as lyophilized powder that requires reconstitution with bacteriostatic water. The reconstitution process, sterility protocols, and peptide purity vary by pharmacy. FormBlends works exclusively with 503B outsourcing facilities that follow current good manufacturing practices (cGMP) and provide certificates of analysis for each batch.

Dosing flexibility. Compounded versions allow for more granular dose adjustments than brand-name pens. If you're experiencing side effects at 5 mg tirzepatide, a compounding pharmacy can prepare a 3.75 mg or 4.0 mg dose. Brand-name pens come in fixed increments.

Supply chain considerations. Compounded medications are only legally available during an FDA-declared shortage. If the FDA removes semaglutide or tirzepatide from the shortage list, compounded versions become unavailable and patients must transition to brand-name products or discontinue treatment. As of April 2026, both medications remain on the shortage list with no announced removal date, but this could change.

Cost transparency. Compounded medication pricing is more transparent than brand-name pricing. The $250 to $450 per month range is the actual out-of-pocket cost. Brand-name medications have list prices of $1,000+ but actual patient cost depends on insurance coverage, manufacturer coupons, and pharmacy benefit manager negotiations. For patients paying cash, compounded versions are almost always less expensive.

The decision tree:

If you're starting GLP-1 therapy for the first time and paying out of pocket:

• Start with compounded semaglutide unless you have 60+ pounds to lose and tolerate nausea well
• Titrate to 1.0 mg and assess weight-loss velocity at week 12
• If losing 1+ pounds per week, stay on semaglutide
• If losing less than 0.5 pounds per week despite adherence, consider switching to tirzepatide

If you're currently on brand-name semaglutide and considering a switch:

• If insurance covers brand-name and out-of-pocket cost is under $50 per month, stay on brand-name
• If out-of-pocket cost is above $100 per month, compounded semaglutide is likely cheaper
• If you've plateaued on semaglutide 2.4 mg, compounded tirzepatide is a reasonable next step

If you're currently on brand-name tirzepatide and considering a switch:

• Same cost calculus as semaglutide
• If you're losing weight consistently on brand-name tirzepatide, the switch to compounded is primarily a cost decision
• Compounded tirzepatide costs 70 to 80% less than brand-name Zepbound

FAQ

Which is better for weight loss, Mounjaro or Ozempic? Mounjaro (tirzepatide) produces 5 to 7 pounds more weight loss than Ozempic (semaglutide) at maximum doses in clinical trials. Tirzepatide 15 mg produces an average of 21% body weight loss versus 15% for semaglutide 2.4 mg over 72 weeks. The difference is statistically significant but clinically modest. Both medications produce meaningful weight loss.

Which has worse side effects, Mounjaro or Ozempic? Mounjaro causes more nausea and vomiting than Ozempic. Nausea rates are 22% for tirzepatide versus 16% for semaglutide. Vomiting rates are 10% versus 8%. Diarrhea rates are slightly higher with semaglutide. Discontinuation rates due to side effects are 6.2% for tirzepatide versus 4.5% for semaglutide.

Is Mounjaro stronger than Ozempic? Yes, in the sense that Mounjaro produces greater weight loss and A1C reduction at maximum doses. Mounjaro is a dual GLP-1 and GIP receptor agonist, while Ozempic is a GLP-1 receptor agonist only. The dual mechanism produces additive effects on weight loss and glucose control but also increases side-effect risk.

Can I switch from Ozempic to Mounjaro? Yes. Switching from semaglutide to tirzepatide is common, especially for patients who have plateaued on semaglutide. Most providers recommend a 4-week washout between medications to minimize overlapping side effects, though this is not strictly required. When starting tirzepatide after semaglutide, begin at the standard 2.5 mg starting dose and titrate normally.

Which is more expensive, Mounjaro or Ozempic? Brand-name Mounjaro and Zepbound cost approximately $1,400 per month. Brand-name Ozempic costs $970 per month and Wegovy costs $1,350 per month. Compounded tirzepatide costs $300 to $450 per month. Compounded semaglutide costs $250 to $350 per month. Tirzepatide is consistently more expensive than semaglutide in both brand-name and compounded forms.

Do Mounjaro and Ozempic work the same way? Both medications activate GLP-1 receptors, which slows gastric emptying, increases insulin secretion, and reduces appetite. Mounjaro also activates GIP receptors, which enhance insulin secretion and improve lipid metabolism. The dual mechanism is why Mounjaro produces greater weight loss than Ozempic.

Which is better for diabetes, Mounjaro or Ozempic? Both medications are highly effective for type 2 diabetes. Mounjaro produces slightly better A1C reductions (2.3 to 2.5 percentage points versus 1.5 to 2.0 points for Ozempic) at maximum doses. The difference is clinically modest. Most patients with baseline A1C between 7.5% and 9.0% will reach target A1C on either medication.

How long does it take to see results with Mounjaro versus Ozempic? Both medications produce noticeable weight loss within 4 to 8 weeks. Peak weight loss occurs between 60 and 72 weeks. The rate of weight loss is slightly faster with Mounjaro (approximately 0.5 pounds per week faster during the first 6 months) but both medications require 12 to 18 months to reach maximum effect.

Can I take Mounjaro and Ozempic together? No. Taking both medications together increases side-effect risk without meaningful additional benefit. Both medications activate GLP-1 receptors, so the effects would be overlapping rather than additive. If one medication isn't working, the appropriate next step is switching to the other or escalating the dose, not combining them.

Does insurance cover Mounjaro or Ozempic? Insurance coverage varies. Most commercial plans cover Ozempic and Mounjaro for type 2 diabetes with prior authorization. Coverage for Wegovy and Zepbound for weight loss is less common. Medicare Part D does not cover GLP-1 medications for weight loss. Medicaid coverage varies by state. Check with your insurance provider for specific coverage details.

Which causes more nausea, Mounjaro or Ozempic? Mounjaro causes more nausea. Nausea rates are 22% for Mounjaro versus 16% for Ozempic in clinical trials. The difference is due to Mounjaro's dual GLP-1 and GIP receptor activation, which produces additive effects on gastric emptying. Most nausea is transient and improves within 2 to 4 weeks of dose escalation.

Is compounded tirzepatide as effective as brand-name Mounjaro? Compounded tirzepatide contains the same active ingredient as brand-name Mounjaro and acts through the same mechanism. Efficacy should be comparable if the compounded product is prepared correctly and contains the stated amount of active ingredient. Compounded medications are not FDA-approved and quality varies by pharmacy. Work with a reputable 503B compounding facility that provides certificates of analysis.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Diabetes Care. 2023.
5. Samms RJ et al. GIP and GLP-1 receptor agonism improves body composition by reducing adiposity. Cell Metabolism. 2023.
6. Lingvay I et al. Real-world effectiveness of tirzepatide and semaglutide in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2025.
7. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
8. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022.
11. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6). Lancet Diabetes & Endocrinology. 2022.
12. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
13. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.